Spring Creek Capital’s TriSalus Life Sciences TLSI Stock Holding History

Spring Creek Capital’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-503,600	Closed	-$4.93M	–	68
2022 Q1	$4.93M	Hold	503,600	–	–	0.2%	84
2021 Q4	$4.98M	Hold	503,600	–	–	0.19%	74
2021 Q3	$5M	Hold	503,600	–	–	0.24%	72
2021 Q2	$4.88M	Hold	503,600	–	–	0.24%	81
2021 Q1	$4.87M	Buy	+503,600	New	+$5.11M	0.21%	84

Other funds holding TLSI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

IPCP

Iron Park Capital Partners New York $621K AUM 73.14% 1-Year Est. Return

Spring Creek Capital's TLSI Position: Q2 2022 in Review

Spring Creek Capital sold out of TriSalus Life Sciences (TLSI) in Q2 2022, closing a stake of 503,600 shares — an estimated $4.93M sold.

Spring Creek Capital first reported a position in TLSI in Q1 2021 and held it in 5 quarters. The position peaked at $5M in Q3 2021. 72 funds tracked by Wall St. Rank hold TLSI as of Q2 2022.

Spring Creek Capital reported no remaining TriSalus Life Sciences position as of Q2 2022 after selling out during the quarter.
Spring Creek Capital sold 503,600 TriSalus Life Sciences shares in Q2 2022, an estimated $4.93M.
Spring Creek Capital first reported a position in TriSalus Life Sciences in Q1 2021 and held it in 5 quarters.
Spring Creek Capital's TriSalus Life Sciences position peaked at $5M in Q3 2021.
72 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.